Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602498 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions
A NA study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT00602498 is a NA study that has completed, run by Roxane Laboratories. The registered enrollment target is 28 participants.
The verdict
NCT00602498, a NA study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The objective of this study was the bioequivalence of a potential generic 500 mg clarithromycin tablet formulation compared with Abbott Laboratories 500 mg clarithromycin tablet, Biaxin® following a single 500 mg dose, administered with food.
Interventions
- DRUG Clarithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2003-03 |
| Est. Completion | 2003-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00602498
The ClinicalTrials.gov registry entry for NCT00602498 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clarithromycin is the first listed.
NCT00602498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00602498 about?
NCT00602498 is a clinical study titled "Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions". The objective of this study was the bioequivalence of a potential generic 500 mg clarithromycin tablet formulation compared with Abbott Laboratories 500 mg clarithromycin tablet, Biaxin® following a single 500 mg dose, administered with food.
What is the current status of trial NCT00602498?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2003-03. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00602498?
The interventions under investigation include: Clarithromycin (DRUG).
Who is sponsoring clinical trial NCT00602498?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.